{"id":2079,"date":"2012-08-15T20:54:12","date_gmt":"2012-08-16T00:54:12","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=2079"},"modified":"2012-08-15T20:55:32","modified_gmt":"2012-08-16T00:55:32","slug":"sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079","title":{"rendered":"Sunshine Biopharma Submits Adva-27a Manuscript and Stock Sees Solid Gain (SBFM)"},"content":{"rendered":"<p>Sunshine Biopharma (OTC: SBFM) rose 16% in today\u2019s over-the-counter market, as the company announced the submission of its Adva-27a manuscript. Sunshine Biopharma opened today\u2019s trading session at a share price of $0.255, touched an intraday high of $0.31 before noon, and eventually traded at $0.29 at the closing bell. Volume traded below average on the other hand, with 58,395 shares exchanging hands.<\/p>\n<p>Today, August 15, 2012, Sunshine Biopharma announced that it has submitted a manuscript detailing Adva-27a preclinical research results for publication in a peer-reviewed scientific journal.<\/p>\n<p>The manuscript, which was prepared by Sunshine Biopharma scientists in collaboration with scientists from Binghamton University in New York and from Ecole Polytechnique in Montreal, contains a substantial amount of data compiled from experiments conducted by these scientists. Adva-27a is Sunshine Biopharma&#8217;s lead anti-cancer compound. Ada-27a has been shown to be effective at killing multidrug-resistant cancer cells in vitro. Multidrug-resistant cancer cells do not respond to any of the chemotherapy drugs currently in use for cancer treatment.<\/p>\n<p>As noted by @pennystock24 on Twitter, <a href=\"https:\/\/twitter.com\/pennystock24\/status\/235813200405348352\">Investor Stock Alerts<\/a>, <a href=\"https:\/\/twitter.com\/pennystock24\/status\/235813175797350401\">Investor Ideas<\/a>, and a few others, promoted Sunshine Biopharma today. There are 11 results found on stockpromoters.com regarding the promotion of Sunshine Biopharma, with the most recent promotions dated August 1, 2012.<\/p>\n<p>Other notable headlines for Sunshine Biopharma include:<\/p>\n<ul>\n<li>August 2, 2012: BUYINS.NET,\u00a0a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance,\u00a0<a href=\"http:\/\/finance.yahoo.com\/news\/buyins-net-issues-sunshine-biopharma-123000349.html\">initiated coverage<\/a> on Sunshine Biopharma after releasing the latest short sale data through July 31, 2012.<\/li>\n<li>July 30, 2012: InvestorIdeas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues <a href=\"http:\/\/finance.yahoo.com\/news\/cfa-commentary-sunshine-biopharma-inc-155700856.html\">CFA commentary<\/a> by Patrick J. Murphy of Murphy Analytics on Sunshine Biopharma and its lead anti-cancer compound, Adva-27a.<\/li>\n<li>July 20, 2012: Sunshine Biopharma announced that it had <a href=\"http:\/\/finance.yahoo.com\/news\/sunshine-biopharma-engages-beta-pharma-123000990.html\">engaged Beta Pharma<\/a> Canada to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug.<\/li>\n<\/ul>\n<p>Sunshine Biopharma was incorporated on August 31, 2006. It is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The company\u2019s lead compound and drug candidate is Adva-27a, a multi-purpose anti-tumor targeted for various forms of cancer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sunshine Biopharma (OTC: SBFM) rose 16% in today\u2019s over-the-counter market, as the company announced the submission of its Adva-27a manuscript. Sunshine Biopharma opened today\u2019s trading [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":2093,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[260,264,3],"tags":[161],"stock_ticker":[],"class_list":["post-2079","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-advancers","category-health","category-small-cap-stock-news","tag-sbfm","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sunshine Biopharma Submits Adva-27a Manuscript and Stock Sees Solid Gain (SBFM) - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sunshine Biopharma Submits Adva-27a Manuscript and Stock Sees Solid Gain (SBFM) - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Sunshine Biopharma (OTC: SBFM) rose 16% in today\u2019s over-the-counter market, as the company announced the submission of its Adva-27a manuscript. Sunshine Biopharma opened today\u2019s trading [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2012-08-16T00:54:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2012-08-16T00:55:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/08\/Screen-Shot-2012-08-15-at-8.18.58-PM.png\" \/>\n\t<meta property=\"og:image:width\" content=\"563\" \/>\n\t<meta property=\"og:image:height\" content=\"313\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fiona Gibson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fiona Gibson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079\"},\"author\":{\"name\":\"Fiona Gibson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e\"},\"headline\":\"Sunshine Biopharma Submits Adva-27a Manuscript and Stock Sees Solid Gain (SBFM)\",\"datePublished\":\"2012-08-16T00:54:12+00:00\",\"dateModified\":\"2012-08-16T00:55:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079\"},\"wordCount\":371,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/08\/Screen-Shot-2012-08-15-at-8.18.58-PM.png\",\"keywords\":[\"SBFM\"],\"articleSection\":[\"Advancers\",\"Health\",\"Small Cap Stock News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079\",\"name\":\"Sunshine Biopharma Submits Adva-27a Manuscript and Stock Sees Solid Gain (SBFM) - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/08\/Screen-Shot-2012-08-15-at-8.18.58-PM.png\",\"datePublished\":\"2012-08-16T00:54:12+00:00\",\"dateModified\":\"2012-08-16T00:55:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/08\/Screen-Shot-2012-08-15-at-8.18.58-PM.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/08\/Screen-Shot-2012-08-15-at-8.18.58-PM.png\",\"width\":563,\"height\":313},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sunshine Biopharma Submits Adva-27a Manuscript and Stock Sees Solid Gain (SBFM)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e\",\"name\":\"Fiona Gibson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg\",\"caption\":\"Fiona Gibson\"},\"description\":\"Fiona is a finance graduate and an expert in analyzing market trends.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\",\"https:\/\/x.com\/@fionahime\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/fiona-gibson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sunshine Biopharma Submits Adva-27a Manuscript and Stock Sees Solid Gain (SBFM) - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079","og_locale":"en_US","og_type":"article","og_title":"Sunshine Biopharma Submits Adva-27a Manuscript and Stock Sees Solid Gain (SBFM) - Wall Street PR","og_description":"Sunshine Biopharma (OTC: SBFM) rose 16% in today\u2019s over-the-counter market, as the company announced the submission of its Adva-27a manuscript. Sunshine Biopharma opened today\u2019s trading [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2012-08-16T00:54:12+00:00","article_modified_time":"2012-08-16T00:55:32+00:00","og_image":[{"width":563,"height":313,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/08\/Screen-Shot-2012-08-15-at-8.18.58-PM.png","type":"image\/png"}],"author":"Fiona Gibson","twitter_misc":{"Written by":"Fiona Gibson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079"},"author":{"name":"Fiona Gibson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e"},"headline":"Sunshine Biopharma Submits Adva-27a Manuscript and Stock Sees Solid Gain (SBFM)","datePublished":"2012-08-16T00:54:12+00:00","dateModified":"2012-08-16T00:55:32+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079"},"wordCount":371,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/08\/Screen-Shot-2012-08-15-at-8.18.58-PM.png","keywords":["SBFM"],"articleSection":["Advancers","Health","Small Cap Stock News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079","url":"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079","name":"Sunshine Biopharma Submits Adva-27a Manuscript and Stock Sees Solid Gain (SBFM) - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/08\/Screen-Shot-2012-08-15-at-8.18.58-PM.png","datePublished":"2012-08-16T00:54:12+00:00","dateModified":"2012-08-16T00:55:32+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/08\/Screen-Shot-2012-08-15-at-8.18.58-PM.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/08\/Screen-Shot-2012-08-15-at-8.18.58-PM.png","width":563,"height":313},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sunshine-biopharma-submits-adva-27a-manuscript-and-stock-sees-solid-gain-sbfm-2079#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Sunshine Biopharma Submits Adva-27a Manuscript and Stock Sees Solid Gain (SBFM)"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e","name":"Fiona Gibson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg","caption":"Fiona Gibson"},"description":"Fiona is a finance graduate and an expert in analyzing market trends.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr","https:\/\/x.com\/@fionahime"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/fiona-gibson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/2079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=2079"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/2079\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/2093"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=2079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=2079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=2079"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=2079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}